Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Corvus Pharmaceuticals, Inc. (CRVS) had Normalized Pre-Tax Income of $-8.00M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-8.00M |
|
-- |
|
-- |
|
$10.26M |
|
$-10.26M |
|
$2.26M |
|
$-8.00M |
|
|
Normalized Pre-Tax Income |
$-8.00M |
$-8.00M |
|
$-8.00M |
|
$-8.00M |
|
$-8.00M |
|
$-10.26M |
|
$-10.56M |
|
77.77M |
|
77.77M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$75.78M |
|
$0.25M |
|
$13.68M |
|
$89.46M |
|
$8.51M |
|
-- |
|
$0.73M |
|
$9.23M |
|
$80.23M |
|
$80.23M |
|
$80.23M |
|
74.51M |
|
| Cash Flow Statement Financials | |
$-14.04M |
|
$-16.06M |
|
$36.05M |
|
$8.74M |
|
$14.69M |
|
$5.95M |
|
$2.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.91 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.19M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.97% |
|
-9.97% |
|
-8.94% |
|
-9.97% |
|
$1.08 |
|
$-0.18 |
|
$-0.18 |
|